The results presented in this study indicate that 68Ga-PSMA radioligand therapy may not be considered specific for thyroid cancer, however targeting of tumor-associated endothelium via PSMA can be a promising strategy for imaging and treatment of RAI-refractory thyroid carcinoma. Here, FOLH1 is linked to thyroid gland carcinoma.